Legal Guidance and Research / Experts / Zina Chatzidimitriadou
Zina Chatzidimitriadou#5366
LinkedIn

Zina Chatzidimitriadou

Sidley Austin
ZINA CHATZIDIMITRIADOU advises life sciences and medtech clients on all aspects of product lifecycle management under UK and EU law. A former scientist, having worked in molecular biology research, Zina brings with her the ability to effectively understand the science. She has a particular focus on advising and speaking on regulatory protections and IP rights, cell and gene therapies, market access, digital health, and artificial intelligence.

Zina’s practice covers the pharmaceutical, medical device, medtech, biotechnology, food, cosmetics, and novel products (such as cannabidiol or CBD) industries on both advisory and contentious matters. Zina also co-leads the industry benchmarking group, ctlegal, for clinical trials in the pharmaceutical industry.

Practice Area

Panel

  • Contributing Author

Qualified Year

  • 2008

Membership

  • Drug Information Association (DIA)
  • IPSoc, the society for junior IP practitioners
  • ChIPS (Chiefs in Intellectual Property)

Qualifications

  • B.A. in Biology (2011)
  • Graduate Diploma in Law (2013)

Education

  • Amherst College (2011)
  • The University of Law (2013)

2 Contributions by Zina Chatzidimitriadou

Clinical research data protection under UK and EU GDPR: DUAA 2025 updates, lawful bases, transparency, secondary use, data sharing, international transfers, safeguards, rights exemptions, and practical checklist
PRACTICE NOTES
Clinical research data protection under UK and EU GDPR: DUAA 2025 updates, lawful bases, transparency, secondary use, data sharing, international transfers, safeguards, rights exemptions, and practical checklist
Data—and by extension, adherence to data protection rules—sits at the heart of clinical research, whether for clinical trials, pharmacovigilance activities or wider scientific inquiry. This Practice Note examines the data protection ramifications of running clinical research. In particular, it addresses who is accountable for compliance, the lawful bases relied upon, and how transparency should be delivered in this context... Allocation of responsibility for data protection compliance in clinical research Appropriate legal grounds for processing personal data for research purposes Transparency duties owed to participants and other data subjects Collaborative research arrangements and data sharing practices Derogations from data subject rights when processing for research A practical checklist of data protection points to consider when planning research activities The GDPR regimes On 25 May 2018, the General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR) became directly applicable and enforceable across all EU Member States and the EEA (the EU plus Iceland, Norway, and Liechtenstein), including the UK at that time, replacing Directive 95/46/EC (the Data Protection Directive). On 31 January 2020, the UK left the EU and EEA and, as a result, the EU GDPR ceased to apply under UK law from the end of the Brexit implementation period...
Life Sciences
COVID-19 life sciences: UK and EU regulatory flexibilities on medicines, devices/PPE, clinical trials, inspections, supply, MDR delay, vaccines, R&D, funding and collaboration [Archived]
PRACTICE NOTES
COVID-19 life sciences: UK and EU regulatory flexibilities on medicines, devices/PPE, clinical trials, inspections, supply, MDR delay, vaccines, R&D, funding and collaboration [Archived]
ARCHIVED : This Practice Note has been archived and is not maintained. Coronavirus (COVID-19) poses an unparalleled test to the global life sciences sector. UK and EU regulators are issuing frequently updated guidance as the situation develops, and are supporting research and development aimed at limiting the spread’s impact. This Practice Note outlines how UK and EU authorities are responding in relation to: clinical trials and regulatory inspections maintaining continuity of supply for medicinal products and medical devices deferral of the application of Regulation (EU) 2017/745 (consolidated 24.04.2020), the Medical Devices Regulation (MDR) It also highlights major R&D initiatives across the UK and EU, and summarises European Commission guidance on collecting and transfusing convalescent COVID-19 plasma. For sector-specific developments and updates on coronavirus, see the Practice Notes: Coronavirus (COVID-19)—EU life sciences tracker [Archived] and Coronavirus (COVID-19)—UK life sciences tracker [Archived]. Medicinal products Regulatory framework adaptations The Commission, the European Medicines Agency (EMA) and the European medicines regulatory network have released a Q&A document, also endorsed by...
Life Sciences
Expert page AD
If you expected to see yourself on this page, click here.